abstract |
The present invention relates to N-{(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5- It relates to the crystal formula of tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (errobixibat), and more specifically, to the crystallization formula I , IV, MeOH-1, EtOH-1, 1-PrOH-1, 2-PrOH-1. The present invention also relates to a process for preparing these crystal formulas and to a pharmaceutical composition containing the crystal formula IV. |